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Abstract
Background: Multiple system atrophy (MSA) is a sporadic disease. Its pathogenesis may involve multiple genetic
and nongenetic factors, but its etiology remains largely unknown. We hypothesized that the genome of a patient
with MSA would demonstrate copy number variations (CNVs) in the genes or genomic regions of interest. To
identify genomic alterations increasing the risk for MSA, we examined a pair of monozygotic (MZ) twins discordant
for the MSA phenotype and 32 patients with MSA.
Results: By whole-genome CNV analysis using a combination of CNV beadchip and comparative genomic
hybridization (CGH)-based CNV microarrays followed by region-targeting, high-density, custom-made
oligonucleotide tiling microarray analysis, we identified disease-specific copy number loss of the (Src homology 2
domain containing)-transforming protein 2 (SHC2) gene in the distal 350-kb subtelomeric region of 19p13.3 in the
affected MZ twin and 10 of the 31 patients with MSA but not in 2 independent control populations (p = 1.04 ×
10
-8, odds ratio = 89.8, Pearson’s chi-square test).
Conclusions: Copy number loss of SHC2 strongly indicates a causal link to MSA. CNV analysis of phenotypically
discordant MZ twins is a powerful tool for identifying disease-predisposing loci. Our results would enable the
identification of novel diagnostic measure, therapeutic targets and better understanding of the etiology of MSA.
Keywords: Multiple system atrophy, copy number variation, phenotypically discordant monozygotic twins, (Src
homology 2 domain containing)-transforming protein 2, subtelomere, ataxia, parkinsonism, disease-susceptibility
gene
Background
Multiple system atrophy (MSA; MIM146500) is a pro-
gressive neurodegenerative disease clinically character-
ized by a variable combination of cerebellar ataxia,
autonomic disturbance, and parkinsonism with a poor
response to levodopa. X-ray computed tomography or
magnetic resonance imaging (MRI) studies of the brain
usually detect atrophy of the cerebellum and brain stem;
MRI also reveals abnormal signal intensity in the white
matter of these structures and in the putamen. The neu-
ropathologic features of MSA are neuronal loss, astro-
gliosis, and argyrophilic glial cytoplasmic inclusions
(GCIs) in oligodendrocytes [1]. GCIs involve the aggre-
gation of insoluble fibrillar a-synuclein [2], and the
SYNA locus has been associated with MSA in some
genetic studies [3,4], but not in others [5]. The neuroi-
maging findings, clinical features, and neuropathologic
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MSA [6]. MSA essentially is a sporadic disorder with
onset in adulthood. The involvement of environmental
factors and epigenetic mechanisms in its pathogenesis
has been postulated; however, its etiology remains lar-
gely unknown.
Recently, copy number variations (CNVs) have been
recognized as important interindividual structural varia-
tions often located in the complex repetitive regions of
the human genome. They account for more nucleotide
variations between individuals than single-nucleotide
polymorphisms (SNPs). Recent studies have indicated
that CNVs are considerable contributors to genomic dis-
eases and disease susceptibility in humans [7,8]. In addi-
tion, researchers have developed a molecular strategy
that takes advantage of the unique genetic characteris-
tics of monozygotic (MZ) twins: they predicted that ana-
lysis of MZ twins discordant for a given disorder (i.e.,
one is affected and the other is not) will provide impor-
tant clues for identifying the underlying genetic mechan-
ism of that disorder [9,10]. Because a genetic difference
between MZ twins is an extreme form of somatic
mosaicism, de novo CNVs observed in the affected co-
twin is a potential characteristic of the CNV region har-
boring the disease-susceptibility gene(s).
Accordingly, we hypothesized that the genome of a
patient with MSA would demonstrate CNVs in the
genes or genomic regions of interest. To test this
hypothesis, we examined whether a pair of MZ twins
discordant for the MSA phenotype display differences in
genomic structure as de novo CNVs and searched for
CNVs in the genomes of 33 patients with MSA, includ-
ing MZ twins. We conducted whole-genome CNV ana-
lysis by using a genome-wide oligonucleotide CNV
microarray and CNV beadchips, both of which focus on
the CNV-rich region of the human genome. To validate
the results of the whole-genome analysis, we character-
ized the genetic alteration by using a region-targeting,
high-density, custom-made oligonucleotide tiling micro-
array. Our research strategy is illustrated in Figure 1.
Throughout these procedures, we searched for CNVs
rare in normal individuals but frequent in patients with
MSA. A gene whose transcription is affected by such
CNVs and whose expression is mostly confined to the
brain must be a crucial candidate for the pathogenesis
of MSA.
Methods
Subjects
The study comprised 33 unrelated patients with MSA
including a pair of MZ twins discordant for the MSA
phenotype (Table 1). All the patients were neurologically
evaluated at the Department of Neurology, Hokkaido
University Hospital, and examined by brain MRI. The
mean (SD) age of MSA onset was 58.1 (8.2) years (age
range = 37-72 years). According to the current consen-
sus criteria, 31 patients had probable MSA (10 with
MSA-P and 21 with MSA-C) and 2 had possible MSA
(one with MSA-P and one with MSA-C) [6]. Of the lat-
ter 2 patients, the affected MZ twin (aged 67 years) sub-
sequently satisfied the criteria for probable MSA-C, with
obvious atrophy of the brainstem and cerebellum on
brain MRI. His disorder began at age 59, but his twin
was asymptomatic during this study (Table 2).
One hundred control subjects were randomly selected
from community-dwelling elderly individuals with no
neurologic diseases (first set of healthy controls; Table
1) [11]. Fisher’s exact test showed no significant differ-
ences in the mean age or male-to-female ratio between
the MSA-affected patients and the first set of control
subjects. In addition, chi-square test showed the absence
of significant deviation in distribution between the
groups. We extracted DNA from peripheral blood leu-
kocytes but not from lymphoblastoid cell lines.
All the subjects gave written informed consent for
genetic analysis. The study was approved by the Medical
Ethics Committees of Hokkaido University Graduate
School of Medicine and Yamagata University Faculty of
Medicine.
Whole-genome CNV microarray analysis of the MZ twins
After labeling with Cy5 (test) or Cy3 (reference) dye, the
DNAs from the MZ twins discordant for the MSA phe-
notype were competitively hybridized in a human CNV
microarray (SurePrint G3 Human CNV 400K Microar-
ray, Agilent Technologies, Santa Clara, CA) and were
washed and scanned according to previously described
procedures [12]. Further, the DNAs were separately
assayed against a single reference sample (NA19000, a
HapMap Japanese male). All the hybridizations were
performed in duplicate, and the dyes were interchanged
between the DNAs in the second hybridization to elimi-
nate a possible dye-specific bias. Moreover, to validate
monozygosity with multiple SNP probes, the DNAs
were hybridized with CytoSNP-12 beadchips (Illumina,
Inc., San Diego, CA) and scanned for the resulting
300,000 SNP calls.
Whole-genome CNV beadchip analysis of the patients
with MSA
We used whole-genome CNV beadchips (57K, i-select
format, Illumina Infinium system; deCODE Genetics,
Inc., Reykjavik, Iceland) with CNV probes to target the
CNV-rich region of the whole genome as previously
described [11]. The probe content comprised 15,559
CNV segments covering 190 Mb or 6% of the human
genome. The platform has been tested among 4,000 Ice-
landic and HapMap samples. The test showed that
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with minor allele frequency of > 5%. Over 3,742 CNV
segments of size range 5-60 kb were defined; these seg-
ments are 18-fold enriched for CNVs compared with
the genome-wide average density [13].
High-density custom-made oligonucleotide tiling
microarray analysis
We fabricated a custom-made microarray comprising
60-mer probes (Agilent Technologies) targeting a 350-
kb genomic region in the distal subtelomeric region of
19p13.3 (Chr. 19: 250,000-600,000 [NCBI Build 36.1,
h g 1 8 ] )a n du s e dt h eA g i l e n tw ebsite [12] to select and
design the custom tiling array for DNA analysis of the
patients with MSA. The tiling microarray experiments
were performed as described previously [11]. For the
twin analysis, the DNAs from the MZ twins were com-
petitively hybridized with custom tiling microarrays as
described for the whole-genome CNV microarray analy-
sis (CNV 400K microarray).
Statistical analysis
Data analysis of the microarray experiments was con-
ducted by using the Aberration Detection Method-2
Figure 1 Strategy for identifying genes susceptible to MSA.
Table 1 Profile of the subjects
Subjects N Male-to-female ratio Age at sampling (range; years)
Patients with MSA 33* 18:15 61.5 ± 8.3 (39-77)
First set of controls 100* 53:47 57.4 ± 8.8 (41-76)
Second set of controls 25 17:8 59.3 ± 8.9 (41-76)
*A pair of MZ twins was included in each group.
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of the combined log2 ratios at a threshold of 5 as was
done in our previous study[14]. The data were centra-
lized, and calls with average log2 ratios of < 0.15 were
filtered to exclude false positives.
Data analysis of the CNV beadchip experiments was
conducted by using DosageMiner software (deCODE
Genetics). The loss/gain analysis consisted of the follow-
ing 4 steps: (1) intensity normalization and GC content
correction, (2) removal of batch effects by using princi-
pal component analysis, (3) calling of clusters by using a
Gaussian mixture model, and (4) determination of CNV
type by using graphical constraints. In brief, CNVs were
identified when CNV events were conspicuous among
the data, because all sample intensities for CNV probes
should increase or decrease relative to those for the
neighboring probes (not in the CNV region). To deter-
mine deviations in signal intensity, we first normalized
the intensities. The normalized intensities for each color
channel were determined by using an equation and fit
formula (deCODE Genetics). A stretch with more than
one marker showing abnormality in copy number com-
pared with a consecutive stretch in the genome is con-
sidered more likely evidence of deletion or gain [13].
Statistical analysis of the clinical data was performed
with chi-square test or Fisher’s exact test in statistical
program R [15].
Results
Whole-genome CNV array analysis of MZ twins
According to a previous molecular strategy, we investi-
gated a pair of MZ twins discordant for the MSA phe-
notype [9,10]. We confirmed their monozygosity on the
basis of > 99% concordant genotypes by SNP beadchip
analysis containing more than 300,000 SNPs.
CGH-based whole-genome CNV oligonucleotide
microarray analysis for initial screening of genome
alterations in the twins revealed putative variations in
each twin. DNA assay against a normal Japanese refer-
ence sample (HapMap NA1900) confirmed the true gen-
otype of the twins. We identified the following 3 regions
with specific copy number loss in the MSA-affected
twin (HK33): a CNV region on 2p25.3 (genomic posi-
tions 3,642,547-3,643,266, with 2 probes [16]), a CNV
region on 4q35.2 (genomic positions 187,590,335-
187,594,679, with 32 probes [16]), and a CNV region on
19p13.3 (genomic positions 249,367-252,260, with 35
probes [16]). The patterns of the 3 CNV regions are dis-
played in Figure S1 in Additional file 1, Figure S2 in
Additional file 2, and Figure S3 in Additional file 3
respectively.
The last region on 19p13.3 is located within the 19p
subtelomere (250 kb from the 19p telomere). Because a
subtelomere is associated with abundant multicopy
repeats or CNVs known as rearrangement hotspots, pre-
disposing individuals to deletion or duplication events
and possible pathogenic alterations, we hypothesized
that this copy number loss on 19p13.3 predisposes indi-
viduals to MSA and thus focused on this region for sub-
sequent analysis.
Whole-genome CNV beadchip analysis of patients with
MSA
We screened 33 patients with sporadic MSA, including
the MZ twins, and a set of 100 controls by whole-gen-
ome CNV beadchip analysis (Table 1). Of the markers
that showed CNVs, 3 genomic regions (i.e., CNV
regions on 4p16.3, 20q13.3, and 19p13.3) displayed fre-
quent copy number loss in 10 patients with MSA but
not the controls (p < 1.0 × 10
-8).
Among the 3 CNV regions with structural differences
between the MZ twins, frequent copy number loss was
observed on 19p13.3, but not on 2p25.3 (Figure S4 in
Additional file 4) and 4q35.2 (Figure S5 in Additional
file 5), in 10 patients with MSA compared with the first
set of controls (p =1 . 0 4×1 0
-8, odds ratio = 89.8, Pear-
son’s chi-square test; Figure 2). Because the 19p13.3
region (comprising the distal 350-kb region and the
proximal 1-Mb region in Figure 2) showed copy number
loss in both the affected MZ twin and 10 patients with
MSA, we focused on this region for further analysis.
High-density tiling microarray analysis of the MZ twins
To validate the results of the CNV screening in both the
affected MZ twin and 10 patients with MSA, we con-
ducted high-density, custom-made oligonucleotide tiling
microarray analysis. The DNAs from the twins were
compared by competitive hybridization (Figure 3a), the
hybridization results were verified by a dye-swap experi-
ment (Figure 3b), and the DNAs were separately hybri-
dized against a normal reference sample (HapMap
NA1900; Figure 3c and 3d). We found heterozygous
copy number loss (deletion) in the distal 350-kb region
on the 19p subtelomere in the MSA-affected twin
(HK33). The deleted region encompasses 4 genes
Table 2 Clinical features and phenotypes of the 33
patients
Evaluation Predominant features Number (%)
At admission Parkinsonism 8 (24)
Cerebellar ataxia > dysautonomia 24 (73)
Dysautonomia 1 (3)
At sampling Probable MSA-P 10 (30)
Possible MSA-P 1 (3)
Probable MSA-C 21 (64)
Possible MSA-C 1 (3)
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Page 4 of 10Figure 2 Genomic region harboring copy number loss on 19p13.3 in patients with MSA. Data measured by CNV 57K beadchip analysis
were analyzed by using the Hidden Malcov Model. The genomic structures of 100 normal control subjects (top) and 33 patients with MSA
(bottom) are horizontally aligned from position 000,000 (left) to position 5,000,000 (right). Each blue square represents copy number loss at each
CNV probe site whereas each red square represents copy number gain. The horizontal blue bars at the bottom show the distal 350-kb region
and proximal 1-Mb region with frequent copy number loss. The asterisks to the bottom left indicate cases of SHC2 deletion. The bottom map
shows the positions of putative genes in the region [16].
Figure 3 High-density custom-made tiling microarray analysis of the MZ twins discordant for the MSA phenotype. (a) Competitive
hybridization of genomic DNA from the MSA-affected twin (HK33) versus that from his twin (HK34). (b) Dye-swap experiment of the normal
twin (HK34) versus his affected twin (HK33). (c) Competitive hybridization of genomic DNA from the MSA-affected twin (HK33) versus that from a
reference Japanese male (HapMap NA1900). (d) Competitive hybridization of genomic DNA from the MSA-affected twin (HK34) versus that from
the reference Japanese male (HapMap NA19000). Each blue line represents a moving average ratio of log2 (Cy5/Cy3). The blue regions indicate
deletions; these loci were defined by dye-swap experiments (red region). The top map shows the positions of putative genes in the region [16].
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Page 5 of 10including the (Src homology 2 domain containing)-
transforming protein 2 (SHC2)g e n eo n1 9 p 1 3 . 3( g e n o -
mic positions 250-400).
High-density tiling microarray analysis of the patients
with MSA
After confirming the absence of statistical differences in
age and gender distribution, we further analyzed the dis-
tal 350-kb region showing copy number loss on the 19p
subtelomere in the 33 patients with MSA against an
additional set of 25 control subjects (second set of con-
trols, Table 1) by using the same custom-made tiling
a r r a ya sf o rt h eM Zt w i n s .A g a i n ,w ef o u n df r e q u e n t
heterozygous copy number loss in this region in 10 of
the 33 patients but not in any of the 25 control subjects.
Figure 4 demonstrates the moving average pattern of the
distal 350-kb region with copy number loss on 19p13.3
in 6 of the 10 patients, and Figure 5 shows a deletion
map of this region in the 10 patients.
Several genes are located in the subtelomeric region
on 19p13.3, which were frequently deleted in the
patients with MSA and the affected MZ twin (Figure 5).
Of these genes, SHC2, which is expressed in the nervous
system, is a prime candidate for MSA predisposition,
because SHC2 impairment reportedly caused neurologic
defects in a mouse model [17,18]. Therefore, heterozy-
gous copy number loss of SHC2 would predispose indi-
viduals to MSA. Other genes in the region, such as
hyperpolarization-activated cyclic nucleotide-gated
potassium channel 2 (HCN2), mucosal vascular addres-
sin cell adhesion molecule 1 (MADCAM1), and fibro-
blast growth factor 22 (FGF22) genes, may also have an
etiologic link to MSA, because they exert their functions
in the nervous system.
Correlation between copy number loss of SHC2 and the
MSA phenotype
Finally, we estimated the copy number loss of SHC2 in
each patient and tested it for correlation with the phe-
notype at sampling (MSA-P vs. MSA-C) and at the
onset of MSA (parkinsonism vs. cerebellar ataxia with/
without autonomic failure) by chi-square test or Fisher’s
exact probability test. However, no significant correla-
tions were noted (data not shown).
Discussion
We employed 2 strategies for investigating MSA-specific
CNVs: examination of de novo CNVs in a pair of MZ
twins discordant for the MSA phenotype and CNV ana-
lysis of 33 patients with MSA, including the MZ twins.
The CNV beadchip analysis enabled direct measurement
of the fluorescent intensity of each marker, which is sui-
table for screening sporadic cases and control popula-
tions. The comparative genomic hybridization (CGH)-
based whole-genome CNV oligonucleotide microarray
enabled comparison of 2 similar genomes, which is ideal
Figure 4 Structure of copy number loss in the 350-kb subtelomeric region on 19p13.3 resolved by high-density tiling microarray. The
moving average log2 ratio (y-axis) is plotted against the genomic position along the chromosome (x-axis). HK06, HK12, HK15, HK19, HK23, and
HK28 represent 6 patients with MSA and HK60c and HK78c represent controls. The dark lines indicate the copy number loss. The light lines and
dotted lines indicate the normal range and median of the average log2 ratios for probes among normal individuals (n = 25), respectively.
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combination of CGH-based genome-wide oligonucleo-
tide CNV microarray and CNV beadchip analysis fol-
lowed by region-targeting, high-density, custom-made
oligonucleotide tiling microarray analysis led us to iden-
tify copy number loss of SHC2 and its neighboring
genes in the 19p13.3 subtelomeric region of the affected
MZ twin and 10 (30%) unrelated patients with MSA.
Despite the limited number of subjects, this frequency is
quite high when compared with those of other disor-
ders: in schizophrenia, for instance, less than 1% in the
patients has pathogenic CNV markers [13]. The copy
number loss of SHC2 in the MSA-affected twin, which
was validated by the population analysis, strongly sug-
gests a causal link between genomic alteration and MSA
phenotype.
Our results support the idea that CNV analysis of
phenotypically discordant MZ twins is a powerful tool
for identifying disease-predisposing loci. They also sup-
port the opinion that molecular analysis of phenotypi-
cally discordant MZ twins is an excellent focus for
studying disease, because genotypic differences between
twins derived from the same zygote highlight somatic
variation [9]. Instances of somatic mosaicism by muta-
tion in specific genes or chromosomal aberrations with
links to disease have been described previously [19,20].
Our results also suggest that somatic mosaicism by
pathogenic mutations affecting disease-susceptibility
genes is observable frequently, rather than as an excep-
tion [9]. Further studies of a larger cohort of MZ twins
discordant for MSA will be particularly useful for more
detailed characterization of the genetic factors predis-
posing individuals to MSA.
We identified frequent heterozygous copy number loss
of SHC2 and the surrounding area on the 19p13.3 sub-
telomeric region. This region contains a substantially
larger number of low copy repeats and segmental dupli-
c a t i o n si nas m a l la r e at h a nt h a ti nt h ew h o l eh u m a n
genome. This complicated repetitive structure has pre-
vented accurate mapping and sequencing analysis of the
region [21]. The presence of numerous low copy repeats
results in instability and can trigger frequent segmental
loss by unequal crossover or end-joining events; there-
fore, such unstable CNV-rich subtelomeric regions are
predisposed to deletion or duplication events [22]. Note-
worthily, locus-specific mutation rates for CNVs or
structural rearrangements are between 10
-6 and 10
-4,a t
least 2 to 4 orders of magnitude (100- to 10,000-fold)
greater than those for point mutations or SNPs [23].
Considering the causes of sporadic disease such as
MSA, the new high mutation rate of CNVs is fascinat-
ing, and should be studied while searching for gene(s)
related to such disorders [8]. CNVs in the distal 350-kb
region of the 19p13.3 subtelomere have not been
described for other neurologic diseases. For instance,
our preliminary CNV beadchip analysis did not detect
specific copy number loss in patients with multiple
sclerosis (unpublished data).
SHC2 was deleted in the affected MZ twin and fre-
quently deleted in the patients with MSA. SHC2 mRNA
is expressed in various human adult tissues, including
the nervous system. None of the CNVs around SHC2
described in the Database of Genomic Variants were
associated with human neurologic disease [16]. In adult
mice, Shc2 expression is limited to the nervous system,
and in rat and mouse embryos, the expression of Shc2
Figure 5 Extent of copy number loss in the 350-kb subtelomeric region on 19p13.3 in the 10 patients with MSA. The horizontal bars
represent the length of the copy number loss region between genomic positions 250,000 (left) and 600,000 (right) in each patient. The extent
of deletion observed in the affected MZ twin (HK33) is also shown. The top map shows the positions of putative genes in the region [16].
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superior cervical ganglia [17,18]. Shc proteins act as
molecular switches in neuron a lc e l ld e v e l o p m e n tf r o m
proliferation to survival and/or differentiation.
Several other genes frequently deleted in patients with
MSA, such as HCN2, MADCAM1,a n dFGF22,a r ea l s o
expressed in nervous tissue. HCN2 contributes to spon-
taneous rhythmic activity in the external segment of the
g l o b u sp a l l i d u s[ 2 4 , 2 5 ] .A u g m e n t e dc u r r e n t st h r o u g h
the channel of an HCN2 variant was described in
patients with febrile seizure syndrome [26]. Human
MADCAM-1 mRNA transcripts are expressed in the
brain and abnormal elevation of MADCAM-1 has been
described in patients with multiple sclerosis [27]. FGF22
plays an essential role in nervous system development
and is expressed by cerebellar granule cells [28]. Copy
number loss of these genes may alter their expression or
produce aberrant or unstable mRNA or protein pro-
ducts. Furthermore, CNVs influence the expression of
not only the genes harboring them but also the genes in
their vicinity extending up to half a megabase [29]. The
mechanism of the influence of CNVs on the phenotype
over multiple gene expressions is yet to be studied.
Specific copy number loss indicates the possibility that
MSA is a genomic disorder derived from genetic hot-
spots harboring unstable structures predisposed to
CNVs. In this regard, rare clustering of MSA within
families could provide information on inherited genetic
variants related to the development of this disorder [30].
Conclusions
Our study provides compelling evidence of heterozygous
copy number loss in the SHC2 region in the affected
MZ twin and one-third of the patients with MSA.
Further studies on the function of SHC2 in the nervous
system help to elucidate the pathogenesis of MSA and
identify novel therapeutic targets for the disease. Studies
of independent populations with MSA and different eth-
nicities are warranted to fully understand the etiology of
MSA, including yet unidentified genetic and/or nonge-
netic factors.
Additional material
Additional file 1: Figure S1 - Pattern of the CNV region on 2p25.3
in the MZ twins discordant for the MSA phenotype by CGH-based
whole-genome CNV microarray analysis. (Top panel) Competitive
hybridization of genomic DNA from the MSA-affected twin (HK33) versus
that from his twin (HK34). (Bottom panel) Dye-swap experiment of the
normal twin (HK34) versus his affected twin (HK33). Each blue line
represents a moving average ratio of log2 (Cy5/Cy3). The blue region
indicates deletion. These loci were defined by dye-swap experiments
(red region).
Additional file 2: Figure S2 - Pattern of the CNV region on 4q35.2
in the MZ twins discordant for the MSA phenotype by CGH-based
whole-genome CNV microarray analysis. (Top panel) Competitive
hybridization of genomic DNA from the MSA-affected twin (HK33) versus
that from his twin (HK34). (Bottom panel) Dye-swap experiment of the
normal twin (HK34) versus his affected twin (HK33). Each blue line
represents a moving average ratio of log2 (Cy5/Cy3). The blue region
indicates deletion. These loci were defined by dye-swap experiments
(red region).
Additional file 3: Figure S3 - Pattern of the CNV region on 19p13.3
in the MZ twins discordant for the MSA phenotype by CGH-based
whole-genome CNV microarray analysis. (Top panel) Competitive
hybridization of genomic DNA from the MSA-affected twin (HK33) versus
that from his twin (HK34). (Bottom panel) Dye-swap experiment of the
normal twin (HK34) versus his affected twin (HK33). Each blue line
represents a moving average ratio of log2 (Cy5/Cy3). The blue region
indicates deletion. These loci were defined by dye-swap experiments
(red region).
Additional file 4: Figure S4 - Pattern of the CNV region on 2p25.3
in the patients with MSA and controls. Data measured by CNV 57K
beadchip analysis were analyzed by the Hidden Malcov Model. The
genomic structures of 100 normal control subjects (top) and 33 patients
with MSA (bottom) are horizontally aligned from position 000,000 (left)
to position 5,000,000 (right). Each blue square represents copy number
loss at each CNV probe site whereas each red square represents copy
number gain.
Additional file 5: Figure S5 - Pattern of the CNV region on 4q35.2
in the patients with MSA and controls. Data measured by CNV 57K
beadchip analysis were analyzed by the Hidden Malcov Model. The
genomic structures of 100 normal control subjects (top) and 33 patients
with MSA (bottom) are horizontally aligned from position 186,000,000
(left) to position 191,000,000 (right). Each blue square represents copy
number loss at each CNV probe site whereas each red square represents
copy number gain.
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